Back to News
Nov 11, 2025 4:00 PM

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India

Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR).

What Happened: According to Reuters, Pfizer Inc (NYSE:PFE) won the bidding war against Novo Nordisk and will purchase Metsera for $10 billion. The board of Metsera accepted Pfizer’s offer, stating that Novo’s bid carried too much legal and regulatory risks following antitrust concerns raised by the Federal Trade Commission.

Along with news of the company’s bidding war, Novo Nordisk reportedly cut the price of Wegovy in India as the company pushes for market share in one of the fastest-growing markets for obesity treatments in the world. Reuters reported that the drugmaker had ...